Scienture Holdings, Inc. (NASDAQ:SCNX) announced on Tuesday that Arbli (losartan potassium) Oral Suspension, 10 mg/mL, has ...

Expanded Coverage Reaches Over 100 Million Covered Lives Nationwide COMMACK, NY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned ...

U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli ™ as the first FDA-approved ready-to-use oral suspension “This represents a paradigm ...

U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli™ as the first FDA-approved ready-to-use oral suspension “The commercial launch of Arbli™ ...

The MarketWatch News Department was not involved in the creation of this content. Novel oral suspension addresses critical patient safety needs for hypertension treatment for patients unable to ...

Hypertension impairs blood vessels, neurons and white matter in the brain well before the condition causes a measurable rise ...

Scienture has commenced selling Arbli, the first FDA-approved ready-to-use liquid losartan formulation. ・The U.S. losartan market is worth about $256 million annually, offering strong growth potential ...

U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli ™ as the first FDA-approved ready-to-use oral suspension COMMACK, NY, Oct. 16, 2025 ...

Reports Significant Revenue Growth to $590K and Substantial Increase in Gross Profit to $575K Launched Sales of Arbli ™ , the First FDA-Approved ...

U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli(TM) as the first FDA-approved ready-to-use oral suspension COMMACK, NY, Oct. 23, 2025 ...

Hypertension impairs blood vessels, neurons and white matter in the brain well before the condition causes a measurable rise in blood pressure, according to a new preclinical study from Weill Cornell ...